“…Throughout the years, several authors have evaluated the impact of targeting early CD on disease outcomes ( Table 1 ). Most of the available evidence comes from the use of anti-TNF drugs, either alone (22 12 – 21 , 23 – 25 , 29 , 31 , 32 , 34 , 35 , 36 , 37 , 38 , 41 out of 29 studies) or in combination with immunosuppressants (7 7 , 17 , 30 , 34 , 38 , 39 , 40 ); the single use of immunosuppressants was evaluated in five studies, 17 , 21 , 28 , 33 , 38 while vedolizumab was studied once. 22 Although ‘early disease’ definition and the outcomes sought varied widely, data from observational studies and from post-hoc analysis of RCTs have shown that patients who received therapy in the early stage of disease have better outcomes than those who received treatment later.…”